68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target for the detection of ccRCC. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG PET/CT in the same group of ccRCC patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• patients with confirmed or suspected clear cell Renal cell carcinoma;

• 68Ga-P16-093 18F-FDG PET/CT within a week;

• signed written consent.

Exclusion Criteria:

• pregnancy;

• breastfeeding;

• known allergy against PSMA;

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.